Article Text

PDF
Randomised controlled trial
Varenicline for 4 weeks prior to target quit date reduces prequit date smoking and increases 12-week abstinence
  1. Gina Daubney Garrison
  1. Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA
  1. Correspondence to Gina Daubney Garrison
    Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA; gina.garrison{at}acphs.edu

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Context

Efficacy of varenicline for tobacco cessation has been attributed to its partial agonist activity at selective nicotinic acetylcholine receptors.1 This mechanism of action is thought to reduce withdrawal symptoms, while competitively occupying receptors linked to reward pathways to decrease smoking enjoyment and intake.1 2 When combined with counselling, varenicline can improve smoking abstinence rates two to threefold.3 4

Most clinical trials of varenicline initiated therapy 1 week prior to target quit date (TQD).3 4 5 In a ‘proof-of-principle’ study, Hajek et al compared varenicline 1 week versus …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.